DK1349944T3 - Latensassocieret peptid af TGF-beta til at bibringe farmaceutisk aktive proteiner latens - Google Patents
Latensassocieret peptid af TGF-beta til at bibringe farmaceutisk aktive proteiner latensInfo
- Publication number
- DK1349944T3 DK1349944T3 DK02729440T DK02729440T DK1349944T3 DK 1349944 T3 DK1349944 T3 DK 1349944T3 DK 02729440 T DK02729440 T DK 02729440T DK 02729440 T DK02729440 T DK 02729440T DK 1349944 T3 DK1349944 T3 DK 1349944T3
- Authority
- DK
- Denmark
- Prior art keywords
- latency
- pharmaceutically active
- fusion protein
- associated peptide
- nucleic acid
- Prior art date
Links
- 101800001155 Latency-associated peptide Proteins 0.000 title abstract 3
- 102400000401 Latency-associated peptide Human genes 0.000 title abstract 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 title 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 abstract 5
- 102000037865 fusion proteins Human genes 0.000 abstract 5
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000006337 proteolytic cleavage Effects 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/756,283 US6942853B2 (en) | 2001-01-09 | 2001-01-09 | Latent fusion protein |
| GBGB0100551.1A GB0100551D0 (en) | 2001-01-09 | 2001-01-09 | Protein |
| PCT/GB2002/000068 WO2002055098A2 (en) | 2001-01-09 | 2002-01-09 | Latency associated peptide for providing latency to pharmaceutically active proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1349944T3 true DK1349944T3 (da) | 2005-07-25 |
Family
ID=26245544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02729440T DK1349944T3 (da) | 2001-01-09 | 2002-01-09 | Latensassocieret peptid af TGF-beta til at bibringe farmaceutisk aktive proteiner latens |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6942853B2 (https=) |
| EP (1) | EP1349944B1 (https=) |
| JP (1) | JP4201253B2 (https=) |
| AT (1) | ATE293169T1 (https=) |
| AU (1) | AU2002219345B2 (https=) |
| DE (1) | DE60203692T2 (https=) |
| DK (1) | DK1349944T3 (https=) |
| ES (1) | ES2240740T3 (https=) |
| GB (1) | GB0100551D0 (https=) |
| WO (1) | WO2002055098A2 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7141392B2 (en) * | 2001-01-09 | 2006-11-28 | Queen Mary And Westfield College | Latent fusion protein |
| US20030219402A1 (en) * | 2002-02-14 | 2003-11-27 | Rutter William J. | Chimeric molecules for cleavage in a treated host |
| JP2009510166A (ja) * | 2005-10-04 | 2009-03-12 | グリーンビル ホスピタル システム | 潜伏性プロサイトトキシンおよびそれらの用途 |
| DE102006009324A1 (de) | 2006-03-01 | 2007-09-06 | Dr.Ing.H.C. F. Porsche Ag | Verfahren und Steuergerät zur Steuerung eines variablen Turbolader-Turbinenströmungsquerschnitts |
| WO2008130382A2 (en) | 2006-10-31 | 2008-10-30 | East Carolina University | Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders |
| GB0724556D0 (en) * | 2007-12-17 | 2008-01-30 | Queen Mary & Westfield College | LAtency associated protein construct with aggrecanase sensitive cleavage site |
| FR2932190A1 (fr) * | 2008-06-10 | 2009-12-11 | Commissariat Energie Atomique | Peptides cycliques fluorescents, procedes de preparation de ceux-ci et utilisation de ces peptides pour mesurer l'activite enzymatique d'une enzyme protease |
| CA2757287C (en) | 2009-03-31 | 2019-09-10 | East Carolina University | Cytokines and neuroantigens for treatment of immune disorders |
| GB0911365D0 (en) | 2009-06-30 | 2009-08-12 | Bioceramic Therapeutics Ltd | Multicomponent glasses for use as coatings and in personal care products |
| EP2553101A4 (en) * | 2010-04-02 | 2013-09-04 | Univ Rochester | PROTEASE-ACTIVATED CYTOKINES |
| EP2878308B1 (en) * | 2013-12-02 | 2018-10-31 | Thomas Harder | Agents and methods for the suppression of T cell activation |
| GB201411506D0 (en) * | 2014-06-27 | 2014-08-13 | Univ London Queen Mary | Modified latency associated protein construct |
| JP6516235B2 (ja) * | 2014-10-31 | 2019-05-22 | 国立大学法人富山大学 | キメラタンパク質及びそれを用いたミクログリア活性阻害剤 |
| CA3100005A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| AU2019271148B9 (en) | 2018-05-14 | 2025-05-29 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
| US12459980B2 (en) | 2018-07-25 | 2025-11-04 | AskGene Pharma, Inc. | IL-21 prodrugs and methods of use thereof |
| CN120463822A (zh) * | 2018-09-27 | 2025-08-12 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| ES2780274A1 (es) * | 2019-02-15 | 2020-08-24 | Consejo Superior De Investig Científicas (Csic) | Cortistatina o un análogo de la misma como agente farmacéuticamente activo en forma latente |
| KR20220023988A (ko) | 2019-05-14 | 2022-03-03 | 웨어울프 세라퓨틱스, 인크. | 분리 모이어티 및 이의 사용 방법 |
| KR20220020879A (ko) | 2019-06-12 | 2022-02-21 | 에스크진 파마, 아이엔씨. | 새로운 il-15 프로드럭 및 이를 사용하는 방법 |
| BR112022009110A2 (pt) | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
| WO2021142471A1 (en) | 2020-01-11 | 2021-07-15 | AskGene Pharma, Inc. | Novel masked cytokines and methods of use thereof |
| GB202004679D0 (en) | 2020-03-31 | 2020-05-13 | Stealthyx Therapeutics Ltd | Modified latercy associated protein construct |
| AU2021254283B2 (en) * | 2020-04-10 | 2025-12-11 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| WO2022115865A2 (en) | 2020-11-25 | 2022-06-02 | Xilio Development, Inc. | Tumor-specific cleavable linkers |
| JP2024511387A (ja) | 2021-03-16 | 2024-03-13 | シートムエックス セラピューティクス，インコーポレイテッド | マスクした活性化可能サイトカイン構成体ならびに関連する組成物及び方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5284763A (en) | 1985-03-22 | 1994-02-08 | Genentech, Inc. | Nucleic acid encoding TGF-β and its uses |
| CA2003886A1 (en) | 1988-12-16 | 1990-06-16 | Anthony F. Purchio | Cloning and expression of simian transforming growth factor-beta 1 |
| ES2083469T3 (es) | 1989-11-22 | 1996-04-16 | Genentech Inc | Peptido asociado a una latencia y utilizaciones del mismo. |
| US5697901A (en) | 1989-12-14 | 1997-12-16 | Elof Eriksson | Gene delivery by microneedle injection |
| BR9406715A (pt) | 1993-05-12 | 1996-02-06 | Genetics Inst | Molécula de DNA isolada célula hospedeira vetor método para produzir uma proteina (BMP-11) polipeptideo de proteina-11 morfogenética de osso purificada (BMP-11) e molécula de DNA quimérica |
| CA2712304C (en) | 1994-06-10 | 2011-10-25 | United States Surgical Corporation | Recombinant chimeric proteins and methods of use thereof |
| US5800811A (en) * | 1995-06-06 | 1998-09-01 | Hall; Frederick L. | Artificial skin prepared from coclagen matrix containing transforming growth factor-β having a collagen binding site |
| CA2232669A1 (en) * | 1995-09-27 | 1997-04-03 | Frances Joanne Morling | Recombinant viruses incorporating a protease cleavable protein |
| DE19701141C1 (de) | 1997-01-16 | 1998-04-09 | Hoechst Ag | Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen |
| US6593132B1 (en) * | 1997-04-30 | 2003-07-15 | Twinstrand Therapeutics Inc. | Ricin-like toxin variants for treatment of cancer, viral or parasitic infections |
| GB2324960A (en) | 1997-05-09 | 1998-11-11 | Univ Manchester | Delivery of naked DNA for wound healing |
| JP3762222B2 (ja) | 1998-10-07 | 2006-04-05 | ストライカー・コーポレーション | 改変型ＴＧＦ−βスーパーファミリータンパク質 |
| JP2004508838A (ja) * | 2000-09-11 | 2004-03-25 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | 組合せ蛍光エネルギー移動タグ及びそれらの使用 |
-
2001
- 2001-01-09 US US09/756,283 patent/US6942853B2/en not_active Expired - Lifetime
- 2001-01-09 GB GBGB0100551.1A patent/GB0100551D0/en not_active Ceased
-
2002
- 2002-01-09 WO PCT/GB2002/000068 patent/WO2002055098A2/en not_active Ceased
- 2002-01-09 ES ES02729440T patent/ES2240740T3/es not_active Expired - Lifetime
- 2002-01-09 JP JP2002555832A patent/JP4201253B2/ja not_active Expired - Fee Related
- 2002-01-09 AU AU2002219345A patent/AU2002219345B2/en not_active Ceased
- 2002-01-09 EP EP02729440A patent/EP1349944B1/en not_active Expired - Lifetime
- 2002-01-09 AT AT02729440T patent/ATE293169T1/de not_active IP Right Cessation
- 2002-01-09 DE DE60203692T patent/DE60203692T2/de not_active Expired - Lifetime
- 2002-01-09 DK DK02729440T patent/DK1349944T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| DE60203692T2 (de) | 2006-03-02 |
| US6942853B2 (en) | 2005-09-13 |
| WO2002055098A2 (en) | 2002-07-18 |
| EP1349944A2 (en) | 2003-10-08 |
| WO2002055098A3 (en) | 2002-11-21 |
| EP1349944B1 (en) | 2005-04-13 |
| AU2002219345B2 (en) | 2006-03-16 |
| ATE293169T1 (de) | 2005-04-15 |
| ES2240740T3 (es) | 2005-10-16 |
| DE60203692D1 (de) | 2005-05-19 |
| JP4201253B2 (ja) | 2008-12-24 |
| US20020151478A1 (en) | 2002-10-17 |
| GB0100551D0 (en) | 2001-02-21 |
| JP2004520031A (ja) | 2004-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1349944T3 (da) | Latensassocieret peptid af TGF-beta til at bibringe farmaceutisk aktive proteiner latens | |
| WO2002008251A3 (en) | Peptides as ns3-serine protease inhibitors of hepatitis c virus | |
| ATE500323T1 (de) | Subtilisin-variante | |
| MXPA03000626A (es) | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c. | |
| WO2002008256A3 (en) | Peptides as ns3-serine protease inhibitors of hepatitis c virus | |
| EA200300381A1 (ru) | Нуклеиновые кислоты и полипептиды нового рецептора | |
| AR008727A1 (es) | COMPOSICIONES Y PROTEINAS DE FUSIoN QUE COMPRENDEN UN POLIPEPTIDO QUE COMPRENDE UNA PORCION INMUNOGENICA DE UNA PROTEINA DE PROSTATA O SU VARIANTE, Y USOS DE LAS MISMAS PARA PREPARAR UN MEDICAMENTO | |
| MXPA03000627A (es) | Nuevos peptidos como inhibidores de proteasa serina-ns3 del virus de la hepatitis c. | |
| DK1337629T3 (da) | Dipeptidylpeptidaser | |
| WO2006090385A3 (en) | Protease inhibitors and method of screening thereof | |
| WO2002008277A3 (en) | Nucleic acids, vectors, host cells, polypeptides, and uses thereof | |
| DK1025237T3 (da) | Human kontrolpunktskinase, hCDS1, præparater og fremgangsmåder | |
| UA91820C2 (ru) | Терапевтическое применение вариантов хемокинов | |
| DK1079849T3 (da) | Anvendelse af HMG-proteiner til fremstilling af lægemidler med cytotoksisk virkning | |
| DK1417222T3 (da) | Isolerede polypeptider baseret på den neutraliserende epitop af p17-proteinet fra HIV egnet til vacciner samt neutraliserende anti-p17-antistoffer, der specifikt genkender nævnte neutraliserende epitop | |
| DK1904529T3 (da) | Anvendelse af Stefin A som et scaffoldprotein | |
| FR2828405B1 (fr) | Vaccin anti-coronavirus | |
| DE60229883D1 (de) | Biologisch aktive peptide | |
| WO2003092736A3 (en) | Peptide nucleic acid conjugates with transporter peptides | |
| ATE503834T1 (de) | Bibliotheken rekombinanter chimärischer proteine | |
| DK1778271T3 (da) | Peptid til behandling af herpesvirusinfektioner | |
| WO2004053117A3 (en) | Serine protease | |
| WO2004074312A3 (en) | Tryptophyllin peptides and uses thereof | |
| ATE281522T1 (de) | Sentrin-spezifische menschliche protease senp1 | |
| WO2002016578A3 (en) | Secreted proteins and methods of using same |